|
MAP3K9 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.88850000082397E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.44459999973768E-07 |
| Normal-vs-Stage2 |
1.382440E-02 |
| Normal-vs-Stage3 |
2.7602999996823E-08 |
| Normal-vs-Stage4 |
2.57569999773111E-08 |
| Stage1-vs-Stage2 |
1.642360E-01 |
| Stage1-vs-Stage3 |
2.638000E-01 |
| Stage1-vs-Stage4 |
5.058300E-02 |
| Stage2-vs-Stage3 |
6.427900E-02 |
| Stage2-vs-Stage4 |
1.894020E-02 |
| Stage3-vs-Stage4 |
4.036600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.30590000322084E-08 |
| Normal-vs-AfricanAmerican |
8.736200E-03 |
| Normal-vs-Asian |
2.79960000004742E-06 |
| Caucasian-vs-AfricanAmerican |
3.731600E-01 |
| Caucasian-vs-Asian |
3.511400E-01 |
| AfricanAmerican-vs-Asian |
1.457410E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.11040004863372E-09 |
| Normal-vs-Female |
3.9150999997517E-07 |
| Male-vs-Female |
1.032580E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.37500000002766E-06 |
| Normal-vs-Age(41-60Yrs) |
4.5821000005386E-07 |
| Normal-vs-Age(61-80Yrs) |
5.90500000008376E-08 |
| Normal-vs-Age(81-100Yrs) |
3.372000E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.754200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.937400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.280200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.798400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.655800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.386000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.093900E-02 |
| Classical-VS-Follicular |
9.757800E-01 |
| Classical-VS-Other |
1.561360E-03 |
| Classical-VS-Normal |
4.19739999979463E-07 |
| Tall-VS-Follicular |
3.554000E-02 |
| Tall-VS-Other |
2.754800E-01 |
| Tall-VS-Normal |
4.92460000001138E-07 |
| Follicular-VS-Other |
1.819750E-03 |
| Follicular-VS-Normal |
1.017260E-04 |
| Other-VS-Normal |
1.91000000038244E-07 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.75740000002622E-07 |
| Normal-vs-N1 |
1.13639999999027E-06 |
| N0-vs-N1 |
2.155400E-01 |
|
|
